John Canepa

About John Canepa

John Canepa is an experienced executive and entrepreneur who has served as an executive in numerous technology and life science companies over his 40 plus year career. The companies include Candel Therapeutics, Inc., a clinical stage biopharmaceutical company developing immunotherapies for cancer patients that completed an initial public offering in 2022; Agilis Biotherapeutics, Inc., a pediatric gene therapy company that was acquired by PTC Therapeutics in 2018; and Asterand Biosciences, a global leader in the procurement and sale of human tissue and tissue-based research solutions for drug and diagnostic development. At Asterand Biosciences, he led the acquisition, rebranding and eventual successful sale of the company in 2017.

Mr. Canepa began his career at Arthur Andersen where he spent more than 20 years working primarily with technology-based enterprises. During that time, Mr. Canepa led the Boston office's technology practice and was the worldwide leader of the firm's life sciences practice.

Mr. Canepa has been a member of the Beth Israel Lahey Board of Trustees since its inception and currently serves as the chair of the finance committee, and a member of the audit, governance and executive committees. John was an active member of the Mount Auburn Hospital community for more than two decades and served as Co-Chair of the hospital’s Board of Trustees.

Mr. Canepa received his undergraduate degree from Denison University and his Master of Finance from Michigan State University.